2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Stomach Neoplasms
1
Somatostatinoma
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Somatostatin Receptor-positive GEP-NET
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Diseases
1
Interventions
telotristat ethyl
1
lutetium Lu 177 dotatate
1
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Heart Disease
×
lutetium Lu 177 dotatate
×
Clear all
NCT04039516
2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2
Unknown
20 enrolled